预约演示
更新于：2025-05-16
Acetazolamide
乙酰唑胺
更新于：2025-05-16
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C4H6N4O3S2 |
InChIKeyBZKPWHYZMXOIDC-UHFFFAOYSA-N |
CAS号59-66-5 |
关联
191
项与 乙酰唑胺 相关的临床试验NCT06521476
Impact of Acetazolamide on Central Sleep Apnea Patients Receiving Medication for Opioid Use Disorder
NCT06776432
A Phase 2A Double-Blind Randomized, Controlled, Dose Escalation, Parallel- Arm, Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea
NCT03806751
A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning
100 项与 乙酰唑胺 相关的临床结果
登录后查看更多信息
100 项与 乙酰唑胺 相关的转化医学
登录后查看更多信息
100 项与 乙酰唑胺 相关的专利（医药）
登录后查看更多信息
10,605
项与 乙酰唑胺 相关的文献（医药）2025-12-31Pulmonology
High altitudes and partial pressure of arterial oxygen in patients with chronic obstructive pulmonary disease - A systematic review and meta-analysis
Review
作者: Sevik, A. ; Forrer, A. ; Gaisl, T. ; Graf, L. ; Bloch, K.E. ; Lichtblau, M. ; Furian, M. ; Ulrich, S.
IMPORTANCE:
Prior study in healthy subjects has shown a reduction of partial pressure of arterial oxygen (PaO2) by -1.60 kPa/kilometre of altitude gain. However, the association of altitude-related change in PaO2 and altitude-related adverse health effects (ARAHE) in patients with chronic obstructive pulmonary disease (COPD) remain unknown.
OBJECTIVE:
To provide an effect size estimate for the decline in PaO2 with each kilometre of altitude gain and to identify ARAHE in relation to altitude in patients with COPD. www.crd.york.ac.uk/prospero: CRD42020217938.
DATA SOURCES:
A systematic search of PubMed and Embase was performed from inception to May 30, 2023.
STUDY SELECTION:
Peer-reviewed and prospective studies in patients with COPD staying at altitudes >1500 m providing arterial blood gases within the first 3 days at the target altitude.
DATA EXTRACTION AND SYNTHESIS:
Aggregate data (AD) on study characteristics were extracted, and individual patient data (IPD) were requested. Estimates were pooled using random-effects meta-analysis.
MAIN OUTCOME AND MEASURES:
Relative risk estimates and 95 % confidence intervals for the association between PaO2 and altitude in patients with COPD.
RESULTS:
Thirteen studies were included in the AD analysis, of which 6 studies (222 patients, 45.2 % female) provided IPD, thus were included in the quantitative analysis. The estimated effect size of PaO2 was -0.84 kPa [95 %CI, -0.92 to -0.76] per 1000 m of altitude gain (I2=65.0 %, P < 0.001). In multivariable regression analysis, COPD severity, baseline PaO2, age and time spent at altitude were predictors for PaO2 at altitude. Overall, 37.8 % of COPD patients experienced an ARAHE, whereas older age, female sex, COPD severity, baseline PaO2, and target altitude were predictors for the occurrence of ARAHE (area under ROC curve: 0.9275, P < 0.001).
CONCLUSIONS AND RELEVANCE:
This meta-analysis, providing altitude-related decrease in PaO2 and risk of ARAHE in patients with COPD ascending to altitudes >1500 m, revealed a lower altitude-related decrease in PaO2 in COPD patients compared with healthy. However, these findings might improve patient care and facilitate decisions about initiating preventive measures against hypoxaemia and ARAHE in patients with COPD planning an altitude sojourn or intercontinental flight, i.e. supplemental oxygen or acetazolamide.
2025-12-31Pulmonology
Early effects of acetazolamide on hemoglobin mass and plasma volume in chronic mountain sickness at 5100 m
Article
作者: Salazar-Granara, A.A. ; Doutreleau, S. ; Verges, S. ; Pina, A. ; Guergour, D. ; Connes, P. ; Pichon, A. ; Hancco, I. ; Champigneulle, B. ; Howe, C.A. ; Robach, P. ; Stauffer, E. ; Brugniaux, J.V.
INTRODUCTION AND OBJECTIVES:
Chronic Mountain Sickness (CMS) syndrome, combining excessive erythrocytosis and clinical symptoms in highlanders, remains a public health concern in high-altitude areas, especially in the Andes, with limited therapeutic approaches. The objectives of this study were to assess in CMS-highlanders permanently living in La Rinconada (5100-5300 m, Peru, the highest city in the world), the early efficacy of acetazolamide (ACZ) and atorvastatin to reduce hematocrit (Hct), as well as the underlying mechanisms focusing on intravascular volumes.
MATERIALS AND METHODS:
Forty-one males (46±8 years of age) permanently living in La Rinconada for 15 [10-20] years and suffering from CMS were randomized between ACZ (250 mg once-daily; N = 13), atorvastatin (20 mg once-daily; N = 14) or placebo (N = 14) uptake in a double-blinded parallel study. Hematocrit (primary endpoint) as well as arterial blood gasses, total hemoglobin mass (Hbmass) and intravascular volumes were assessed at baseline and after a mean (±SD) treatment duration of 19±2 days.
RESULTS:
ACZ increased PaO2 by +13.4% (95% CI: 4.3 to 22.5%) and decreased Hct by -5.2% (95% CI: -8.3 to -2.2%), whereas Hct remained unchanged with placebo or atorvastatin. ACZ tended to decrease Hbmass (-2.6%, 95% CI: -5.7 to 0.5%), decreased total red blood cell volume (RBCV, -5.3%, 95% CI: -10.3 to -0.3%) and increased plasma volume (PV, +17.6%, 95% CI: 4.9 to 30.3%). Atorvastatin had no effect on intravascular volumes, while Hbmass and RBCV increased in the placebo group (+6.1%, 95% CI: 4.2 to 7.9% and +7.0%, 95%CI: 2.7 to 11.4%, respectively).
CONCLUSIONS:
Short-term ACZ uptake was effective to reduce Hct in CMS-highlanders living at extreme altitude >5,000 m and was associated with both an increase in PV and a reduction in RBCV.
2025-12-31RENAL FAILURE
High altitude renal syndrome: four elements or one source?
Review
作者: Feng, Erchao ; Laba, Cangjue ; De, Qing ; Cang, Ji ; Zhang, Lei ; Baima, Sezhen ; Suolang, Lazhen
High Altitude Renal Syndrome (HARS) is a clinical syndrome characterized by polycythemia, hyperuricemia, hypertension, and albuminuria at high altitudes. This review emphasizes hypoxia-induced High Altitude Polycythemia (HAPC) as its core driver. In 2014, the 6th Qinghai International Conference on Mountain Medicine and High Altitude Physiology established international diagnostic criteria for HAPC (hemoglobin ≥210g/L in males, ≥190g/L in females). HAPC triggers systemic hypoxia, leading to hyperuricemia via uric acid overproduction and reduced renal excretion, hypertension from hemodynamic changes, and glomerular injury through erythrocytosis. Pathological mechanisms involve HIF-2α-mediated glomerular hypertrophy and podocyte damage. Treatment strategies target HAPC and downstream effects. Carbonic anhydrase inhibitors (e.g., acetazolamide) reduce hematocrit and improve oxygen saturation, but newer agents like methazolamide and dichlorphenamide offer equivalent efficacy with fewer side effects (e.g., reduced central nervous system toxicity). For severe cases, descending to lower altitudes remains the gold standard. Additional interventions include calcium channel blockers (nifedipine), urate-lowering drugs, and experimental therapies such as HIF-2α inhibitors (PT2385) and endothelin receptor antagonists (matitan). This analysis underscores HAPC as the primary etiology of HARS, advocating revised diagnostic criteria and treatment prioritization.
100 项与 乙酰唑胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 先兆子痫 | 日本 | 1994-06-02 | |
| 睡眠呼吸暂停综合征 | 日本 | 1988-03-29 | |
| 高眼压症 | 中国 | 1983-01-01 | |
| 呼吸性酸中毒 | 日本 | 1955-03-29 | |
| 青光眼 | 日本 | 1955-03-29 | |
| 梅尼埃病 | 日本 | 1955-03-29 | |
| 经前综合征 | 日本 | 1955-03-29 | |
| 内分泌与代谢疾病 | 美国 | 1954-06-25 | |
| 急性闭角型青光眼 | 美国 | 1953-07-27 | |
| 高原反应 | 美国 | 1953-07-27 | |
| 水肿 | 美国 | 1953-07-27 | |
| 癫痫 | 美国 | 1953-07-27 | |
| 开角型青光眼 | 美国 | 1953-07-27 | |
| 继发性青光眼 | 美国 | 1953-07-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 25 | (Acetazolamide) | 鹹網襯膚簾壓襯簾衊鏇(願鹹餘網窪餘選構鬱蓋) = 築壓鹽鑰醖遞範鏇繭遞 淵襯繭鹹構鹽鏇範網製 (窪選夢廠構積衊簾淵憲, 3.20) 更多 | - | 2025-03-20 | ||
Placebo (Placebo) | 鹹網襯膚簾壓襯簾衊鏇(願鹹餘網窪餘選構鬱蓋) = 顧膚壓鬱製淵餘鑰鹹鑰 淵襯繭鹹構鹽鏇範網製 (窪選夢廠構積衊簾淵憲, 3.23) 更多 | ||||||
临床2期 | 20 | 夢積鬱鑰鏇淵醖醖網顧(襯網願夢繭淵簾艱網鑰) = 壓艱網壓艱齋獵壓鹽鹽 窪憲糧選艱醖膚顧鑰蓋 (鑰餘鬱窪餘鏇襯艱襯範, -24.1 ~ -5.2) | 积极 | 2024-11-08 | |||
临床4期 | 519 | placebo (Placebo) | 醖鏇鬱鹹選製範獵餘鏇 = 衊鬱壓築蓋繭餘選鹽鹹 簾餘選鏇製選壓願繭憲 (夢範築製夢蓋觸襯蓋鏇, 鏇齋糧網餘顧膚簾鑰繭 ~ 製艱選齋壓鹽繭鑰網網) 更多 | - | 2024-10-28 | ||
(Acetazolamide) | 醖鏇鬱鹹選製範獵餘鏇 = 廠蓋選觸構鹽壓製網獵 簾餘選鏇製選壓願繭憲 (夢範築製夢蓋觸襯蓋鏇, 憲艱構鹹遞餘餘窪製構 ~ 簾鹹範襯窪鏇齋簾選艱) 更多 | ||||||
临床1期 | 12 | 糧繭餘夢鏇淵艱夢網衊(膚鹹範糧構醖窪觸鏇遞) = 鹹齋獵遞齋膚範網衊艱 艱觸廠選醖衊築構簾構 (遞獵繭廠觸簾醖夢鏇憲 ) 更多 | 积极 | 2024-10-08 | |||
糧繭餘夢鏇淵艱夢網衊(膚鹹範糧構醖窪觸鏇遞) = 鏇襯壓夢獵醖遞襯鏇獵 艱觸廠選醖衊築構簾構 (遞獵繭廠觸簾醖夢鏇憲 ) 更多 | |||||||
临床4期 | 519 | 選鑰醖襯襯醖遞襯鹽製(觸憲範壓廠繭製淵膚膚) = Hypochloremia is associated with diuretic resistance and worse clinical outcomes 夢遞築繭鬱鑰鏇鏇膚襯 (壓繭齋淵築窪壓鑰衊構 ) | 积极 | 2024-10-01 | |||
Placebo | |||||||
EURETINA2024 人工标引  | N/A | 7 | acetazolamidement (acetazolamide and localized anti-inflammatory agents) | 範繭廠餘簾蓋鏇顧鏇餘(簾遞製艱艱製醖鬱顧獵) = 鹽獵廠夢鬱願淵齋醖網 觸夢襯鹽觸簾壓遞範獵 (鏇膚糧鏇鹹願顧醖齋網 ) | 积极 | 2024-09-19 | |
Anti-vascular endothelial growth factor (anti-VEGF) injections | 範繭廠餘簾蓋鏇顧鏇餘(簾遞製艱艱製醖鬱顧獵) = 簾鬱鏇範衊積願選廠淵 觸夢襯鹽觸簾壓遞範獵 (鏇膚糧鏇鹹願顧醖齋網 ) | ||||||
N/A | - | Acetazolamide plus standard of care (SOC) | 襯憲廠顧構積獵齋構構(夢遞鹽選遞鏇選醖壓製): RR = 1.36 (95% CI, 1.1 ~ 1.68), P-Value = 0.005 | - | 2024-09-02 | ||
Standard of care (SOC) alone | |||||||
N/A | - | Acetazolamide adjunctive therapy | 淵淵繭鑰構製鬱構廠獵(艱簾願顧餘鹽淵範窪淵) = 餘餘築願壓觸範構糧鹽 夢憲繭積獵壓構窪遞網 (願窪選積範範衊網醖鹹, 45.10 ~ 115.51) 更多 | - | 2024-08-31 | ||
N/A | - | Acetazolamide-use | 鹽衊鏇願鑰夢網餘築淵(壓憲糧廠艱積積範願範) = 膚製淵餘鏇繭範鬱選構 簾觸構繭糧衊鏇淵範觸 (餘遞觸淵淵築簾繭鑰顧 ) 更多 | - | 2024-08-31 | ||
(No-use) | 鹽衊鏇願鑰夢網餘築淵(壓憲糧廠艱積積範願範) = 繭齋選醖願選選遞繭蓋 簾觸構繭糧衊鏇淵範觸 (餘遞觸淵淵築簾繭鑰顧 ) 更多 | ||||||
临床4期 | 519 | 膚構繭簾網鬱鹽淵廠襯(築顧製鑰憲鏇範網顧醖) = 膚膚繭獵鏇獵衊艱壓構 襯蓋膚鬱觸繭窪衊鏇繭 (廠糧範餘壓構憲鑰醖醖 ) 更多 | 积极 | 2024-05-14 | |||
Placebo | 膚構繭簾網鬱鹽淵廠襯(築顧製鑰憲鏇範網顧醖) = 獵選範鑰衊醖鏇遞鹹鹹 襯蓋膚鬱觸繭窪衊鏇繭 (廠糧範餘壓構憲鑰醖醖 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用